Experienced trio to guide Immodulon's IMM-101 through late clinical development

UK-based cancer immunotherapy company Immodulon has named Richard Davies as its new chairman of the board, appointed Gertjan Bartlema chief executive and brought in Peter Greaney as chief business officer.

Together, they bring decades of industry experience from drugmakers including Celgene, Amgen (Nasdaq: AMGN), Hospira, ADC Therapeutics (NYSE: ADCT) and Alvotech (Nasdaq: ALVO). Immodulon sees their expertise as important in guiding IMM-101 through late-stage clinical development and maximizing its potential for patients.

"Immodulon has generated compelling Phase II data with IMM-101, which has the potential to make a real impact on the treatment of pancreatic cancer where patients have limited new treatment options"Mr Davies, who is currently deputy chairman of the board of directors for Alvotech and was formerly chief commercial officer at Hospira, said: “I am excited to join Immodulon’s board of directors as chairman at this pivotal time for the company.